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Summary. Background: Thrombolysis is conventionally regar-
ded as dissolution of the ﬁbrin matrix of thrombi by plasmin,
but the structure of clots in vivo includes additional constitu-
ents (proteins, phospholipids) that modulate their solubiliza-
tion. Objective: W ee x a m i n e dt h ep r e s e n c eo ff r e ef a t t ya c i d si n
thrombi and their eﬀects on distinct stages of ﬁbrinolysis
(plasminogen activation, plasmin activity). Methods and Re-
sults: Using the ﬂuorescent probe acrylodated intestinal fatty
acid-binding protein, variable quantities (up to millimolar
concentrations) of free fatty acids were demonstrated in
surgically removed human thrombi. Oleic acid at relevant
concentrations reversibly inhibits more than 90% of the
amidolytic activity of plasmin on a synthetic substrate (Spec-
trozyme PL), but only partially inhibits its ﬁbrinolytic activity
measured using turbidimetry. Chromogenic assays detecting
the generated plasmin activity show that plasminogen activa-
tion by tissue-type plasminogen activator (t-PA) is completely
blocked by oleic acid in the ﬂuid phase, but is accelerated on a
ﬁbrin matrix. A recombinant derivative of t-PA (reteplase)
develops higher ﬁbrin speciﬁcity in the presence of oleic acid,
because both the inhibition of plasminogen activation in free
solution and its enhancement on ﬁbrin template are stronger
thanwithwild-typet-PA. Conclusion:Throughthestimulation
of plasminogen activation on a ﬁbrin template and the
inhibition of plasminogen activators and plasmin in the ﬂuid
phase,freefattyacidsconﬁnetheactionofﬁbrinolyticproteases
to the site of clotting, where they partially oppose the
thrombolytic barrier function of phospholipids.
Keywords: ﬁbrinolysis, oleic acid, plasmin, reteplase, tissue-
type plasminogen activator.
Introduction
When thrombi are formed within blood vessels, cells (platelets
and leukocytes) inﬁltrate the ﬁbrin matrix and later profoundly
affect proteolytic dissolution by plasmin (reviewed in [1,2]). The
recently described thrombolytic barrier function of phosphol-
ipids [3] is based on diffusion limitations and intermolecular
interactions with ﬁbrinolytic enzymes. In a phospholipid
environment, both the conversion of plasminogen to plasmin
by plasminogen activators [e.g. tissue-type plaminogen activa-
tor (t-PA)] and the proteolytic action of plasmin are signiﬁ-
cantly retarded. Although there are only traces of free fatty
acids in resting platelets [4], as part of their activation
mechanism phospholipase A2 (PLA2) stored in secretory
granules is released and activated [5–7]. Thus, PLA2 hydrolyzes
the ester bond at the sn-2 position of the phospholipids,
releasing a free fatty acid and lysophospholipid. Considering
the millimolar concentration of phospholipids in arterial
t h r o m b i[ 3 ] ,P L A 2 from entrapped cellular elements (platelets
and leukocytes) could, hypothetically, release large quantities
of free fatty acids (mainly oleic acid, because it occupies more
than 54% of the sn-2 ester bonds in platelet phospholipids [4]).
The data on the impact of free fatty acids on the ﬁbrinolytic
system are scarce and controversial. The amidolytic activity of
plasminonsmallsyntheticsubstratesisreportedtobestimulated
byoleicacid[8,9],whereasplasmindigestionofmacromolecules
(ﬁbrin, prostromelysin-1) is inhibited [9,10]. The modulation of
theplasminactivityisprobablymediatedbythebindingofoleic
acid to the kringle-5 domain of the enzyme [9]. Among the
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doublebonds,oleicacidprovedtobethemostpotentinitseffect
on the action of plasmin [9,10]. The inﬂuence of fatty acids on
plasminogen activation is even less well characterized. Only one
plasminogen activator (urokinase) has been evaluated in this
respect, and stimulation of its activity by oleic acid has been
reported [9,10]. No data on the modulation of other activators
and the inhibitors of ﬁbrinolysis are available.
The thrombolytic agents currently approved for treatment
of myocardial infarction and ischemic stroke are all plasmi-
nogen activators with more or less frequent hemorrhagic side-
effects, which led to a search for new ﬁbrin-speciﬁc plasmi-
nogen activators. However, administration of ﬁbrin-binding
thrombolytics (t-PA) did not overcome the bleeding compli-
cations [11]. Reteplase is a recombinant variant of t-PA,
which consists of the kringle-2 and the protease domains of
the wild-type activator (reviewed in [12]). As expected from
the lack of the ﬁnger domain, reteplase has lower afﬁnity for
ﬁbrin, but clinical trials have shown that it produces faster
reperfusion than t-PA, even at lower doses, and without any
increase in the rate of bleeding side-effects, despite a moderate
decrease in ﬁbrinogen levels [13]. This apparent discrepancy
between the clinical proﬁle and the lack of ﬁbrin selectivity of
reteplase can be partially explained by its slower clearance in
circulation, but, as our present study shows, evaluation of the
activator in models that approach the complex composition
of thrombi provides better understanding of its in vivo
thrombolytic properties.
Methods
Preparation of LUVs
Dipalmitoyl-phosphatidylcholine (PC), dipalmitoyl-phosphat-
idylserine (PS), palmitoyl-oleoyl-phosphatidylcholine (poPC)
and lysophosphatidylcholine (1-palmitoyl) (lysoPC) (Sigma-
Aldrich Kft., Budapest, Hungary) were weighed, mixed at the
desired mass ratio, and dissolved in chloroform/methanol (95:5
volume ratio). Following evaporation of the solvent, the
phospholipids were suspended with brief sonication, and large
unilamellar phospholipid vesicles (LUVs) were prepared by
extrusion through a 50-nm-diameter polycarbonate ﬁlter in a
Liposofast mini-extruder (Avestin Inc., Ottawa, Canada) [16].
The concentration of phospholipids in the LUV suspension
was determined with the ﬂuorescent probe 1,6-diphenyl-1,3,5-
hexatriene [17]. The LUVs designated as poPCPS contained
poPC, PC and PS mixed at 2:3:5 weight ratio.
Turbidimetric ﬁbrinolytic assay
This was carried out as previously described [15]. Brieﬂy,
100 lLo f6lmol L
)1 ﬁbrinogen (Calbiochem, LaJolla, CA,
USA) containing 0.25 lmol L
)1 plasminogen (isolated from
human plasma [18]), 1 mg mL
)1 LUVs (poPCPS) and
0.5 mg mL
)1 PLA2 (Sigma-Aldrich Kft., Budapest, Hungary)
was clotted with 0.01 lmol L
)1thrombin in microplate wells at
37  C for 45 min. The dissolution of the clots was induced by
100 lL of t-PA (Boehringer Ingelheim, Ingelheim, Germany)
applied on the surface of the clot at concentrations in the range
10–120 nmol L
)1,a n d6 0lL of mineral oil was layered over
the solution to prevent evaporation. The course of clot
formation and dissolution was monitored by measuring the
light absorbance at 340 nm at 37  C with a Zenyth 200rt
microplate spectrophotometer (Anthos Labtec Instruments
GmbH, Salzburg, Austria). The lysis time (t1/2), deﬁned as the
time needed to reduce the turbidity of the clot to a half-
maximal value, was used as a quantitative parameter of
ﬁbrinolytic activity. In certain experiments, a2-plasmin inhib-
itor (a2PI; Sigma-Aldrich Kft., Budapest, Hungary) was added
to ﬁbrinogen prior to clotting.
Plasminogen activation assays
Plasminogen activation in homogeneous solution was evalu-
ated as previously described [14]. Brieﬂy, 3 lmol L
)1 plasmi-
nogen containing fatty acids at various concentrations (a
14 mmol L
)1 stock solution of fatty acids in ethanol was
further diluted in 10 mmol L
)1 HEPES buffer (pH 7.4)
containing 150 mmol L
)1 NaCl) was mixed with 70 nmol L
)1
t-PA, samples were taken at intervals, and the amidolytic
activity of the generated plasmin was measured on
0.1 mmol L
)1 Spectrozyme-PL (H-D-norleucyl-hexahydrotyr-
osyl-lysine-p-nitroanilide; American Diagnostica, Hartford,
CT, USA). Ethanol at concentrations equivalent to the amount
included in the reaction mixtures as a solvent of fatty acids did
not affect this assay, in agreement with an earlier report [8].
Plasminogen activation in the presence of ﬁbrin was measured
on the surface of clear ﬁbrin clots (A405 < 0.1) [19] prepared in
standard 96-well microtiter plates from 20 lLo f0 . 2lmol L
)1
thrombin and 60 lLo f4 . 4 lmol L
)1 ﬁbrinogen in
10 mmol L
)1 HEPES (pH 7.4) buffer containing
200 mmol L
)1 NaCl and 0.1 lmol L
)1 plasminogen. After
30 min of incubation at 37  C, 60 lL of plasminogen activator
(t-PA or reteplase from Centocor, Malvern, PA, USA) in
10 mmol L
)1 HEPES (pH 7.4) buffer containing
150 mmol L
)1 NaCl and 0.6 mmol L
)1 Spectrozyme-PL or
S-2251 (H-D-valyl-L-leucyl-L-lysine-p-nitroanilide; Chromoge-
nix SpA, Milan, Italy) was layered on the clot surface, followed
by 60 lL of mineral oil. The light absorbance at 405 nm (A405)
indicating the release of p-nitroaniline by the generated plasmin
was continuously recorded with a Zenyth 200rt microplate
spectrophotometer at 37  C. The measured A405 values were
plotted vs. time squared, yielding a linear relationship with a
slope directly proportional to the rate of plasminogen activa-
tion. If, at time t0 = 0, there was no plasmin in the reaction
system, then according to [20], DA405 =0 . 5 ek1k2[PA]t
2,w h e r e
e is the extinction coefﬁcient for p-nitroaniline (3.82 mmol
)1 L
determined for the volume of our assay system), k1 = 13.5 s
)1
is the turnover number of plasmin on Spectrozyme PL [21], and
k2 and [PA] are the apparent reaction rate constant for
plasminogen activation in this assay and the concentration of
the plasminogen activator, respectively.
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Fatty acids were removed from the commercial bovine serum
albumin (BSA; Sigma-Aldrich Kft., Budapest, Hungary) by
charcoal treatment at pH 2.5 according to a published
procedure [22]. Protein concentration was determined from
the absorbanceat 280 nmusinganextinctioncoefﬁcient of 0.67
f o rt h e1gL
)1 albumin solution.
Free fatty acid release from phospholipids
The release of free fatty acids from LUVs by PLA2 was
measured with the ﬂuorescent probe acrylodated intestinal
fatty acid-binding protein (ADIFAB) (Molecular Probes,
Leiden, the Netherlands) [23]. LUVs (1 g L
)1 phospholipid
concentration) were incubated with 0.5 mg mL
)1 PLA2 in
10 mmol L
)1 HEPES (pH 7.4) buffer containing
150 mmol L
)1 NaCl and 3 mmol L
)1 CaCl2 in the presence
of 0.2 lmol L
)1 ADIFAB at 37  C in a 1-mL ﬂuorimetric
cuvette. The emission ratio at 505 and 432 nm (excitation
386 nm) was monitored continuously for 30 min with a
Photon Technology International (PTI; Lawrenceville, NJ,
USA) Deltascan ﬂuorescence spectrophotometer. The free
fatty acid concentration was determined from a calibration
curve generated for known concentrations of sodium oleate in
the presence of 1 g L
)1 LUVs.
Detection of free fatty acids in thrombi
Thrombi were surgically removed from the femoral artery,
aortoiliac aneurysm, femoropopliteal graft or saphenous vein
of four patients with hyperlipidemia and generalized athero-
sclerosis. Patients gave informed consent, and permission was
obtained from the local ethics committee. After the thromb-
ectomy, the samples were frozen immediately at – 70  Ca n d
stored until examination. Cryosections (5 lm · 1.5 cm ·
1.5 cm) of thrombi were prepared without ﬁxation, and
i m m e r s e di n1 0 0lLo f2lmol L
)1 ADIFAB on glass plates
for 10 min. Thereafter, the spatial pattern of ﬂuorescence at
460 nm (excitation 390 nm) was measured with a scanning
ﬂuorescence spectrophotometer (Fluoroskan Ascent FL, Lab-
systems Oy, Helsinki, Finland).
Results
Surgically removed human thrombi were examined for the
presence of free fatty acids and estimation of their concentra-
tion. The probe ADIFAB indicated highly variable amounts of
free fatty acids in the thrombectomy samples. In ﬁve of eight
thrombi examined by us, the free fatty acids present in the
thrombus sections completely quenched the ﬂuorescence of the
appliedADIFAB(Fig. 1A),whichisequivalentto20 lmol L
)1
sodium oleate in the same volume of ADIFAB (Fig. 1C). The
original ﬂuorescence of ADIFAB (Fig. 1D), however, was not
changed in three of the examined thrombi (Fig. 1B). Thus, the
amount of free fatty acids in thrombi spans a range from
undetectable levels up to millimolar concentrations (fatty acids
from 1 lL of thrombus saturate 0.2 nmol L ADIFAB).
The effects of fatty acids on ﬁbrinolysis were analyzed with
in vitro assay systems. We modeled the overall course of
thrombolysis induced by t-PA under the changing conditions
of ongoing hydrolysis of phospholipids with ﬁbrin–phosphol-
ipid clots containing PLA2 (at a concentration releasing
1.97 lmol L
)1 min
)1 fatty acid from LUVs). In order to
identify the effects of the phospholipid hydrolytic products,
which are not related simply to the elimination of the
phospholipids, we assembled ﬁbrin clots with a poPCPS
mixture, the melting temperature of which is 33  C [24]. This
phospholipid only mildly affected the course of ﬁbrinolysis at
37  C, in agreement with our previous ﬁndings that an ordered
gel phase is required for the inhibitory effects of phospholipids
on clot dissolution [3]. However, when the concentration of free
fatty acid released by PLA2 increased to over 0.24 mmol L
)1
(measured with ADIFAB), the dissolution process was signi-
ﬁcantly accelerated. Because LUVs containing lysophosphol-
ipid (the other product of the PLA2action on phospholipids) at
the same concentration did not affect the clot dissolution, we
restricted our further experiments to the effects of fatty acids.
Using an assay speciﬁc for plasminogen activation on a
ﬁbrin surface [19], signiﬁcant acceleration of plasmin genera-
tion was measured in the presence of oleic acid with the ﬁbrin-
binding activators t-PA and reteplase (Fig. 2), but not with the
non-ﬁbrin-binding activator urokinase (not shown). The acti-
vation with reteplase was more sensitive to the effect of the oleic
acid than that with t-PA; identical fatty acid concentrations
caused greater stimulation of the reaction rate with reteplase
(Fig. 2, insets; Table 1). Because Spectrozyme-PL is known to
affect plasminogen activation under certain conditions,
whereas S-2251 does not [25], the experiments shown in
Fig. 2 were repeated with this alternative plasmin substrate. At
concentrations of oleic acid up to 0.5 mmol L
)1, the assay with
S-2251 showed the same pattern of acceleration (data not
shown), indicating that the observed stimulation does not
depend on the type of detection substrate. At higher oleic acid
concentrations, however, the absorbance progress curves
reached plateaus at much lower values than in the Spectro-
zyme-PL system, resulting in a loss of sensitivity, which can be
attributed to the different Km values of the two substrates for
plasmin (266 lmol L
)1 for S-2252 [19] vs. 10 lmol L
)1 for
Spectrozyme-PL [14]).
The template function of ﬁbrin seems to be essential for the
stimulatory effect of oleic acid, because no activation was seen
in the absence of template (Fig. 3A), and only a transient
plasmin activity could be detected in the presence of a soluble
template, cyanogen bromide human ﬁbrinogen fragment
(FgDP) (Fig. 3B). The loss of plasmin activity in the experi-
mental setting of Fig. 3B, as well as in the later stages of the
ﬁbrin-dependent plasminogen activation assay (Fig. 2), was a
surprising result in the light of earlier reports on stimulation of
the plasmin amidolytic activity on small substrates by oleic acid
[8,9], and prompted evaluation of the activator and plasmin
activities in ﬁbrin-free systems.
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by oleic acid was seen when the action of 1 nmol L
)1 plasmin
on 0.1 mmol L
)1 Spectrozyme PL was monitored for a period
of 30 min in an assay system free of additional proteins and
detergents. This effect, however, is related to adsorption of the
enzyme to the plasticware, which is prevented by the detergent
effect of the fatty acid. When shorter incubation with a higher
concentration of plasmin (25 nmol L
)1)w a su s e di nt h e
amidolytic assay, the magnitude of this interference was
negligible, and a deﬁnite inhibition of the plasmin activity was
observed (Fig. 4). Plasmin inhibition could be reversed slowly
by BSA, which binds the free fatty acids, or by dilution of
the plasmin–oleic acid mixture (Fig. 4, inset). Similar (but
weaker) effects on the amidolytic activity of plasmin are
produced by arachidonic acid (data not shown). The ﬁbrin-
olytic activity of plasmin, however, was not affected to the
same degree as its amidolytic activity (Fig. 5). The presence of
oleic acid in the ﬁbrin clot did not affect the lysis rate with
plasmin applied to its surface without oleic acid (data not
shown).
The combination of plasminogen activation in ﬂuid phase
and on a ﬁbrin template in a single assay provided further
evidence for the role of ﬁbrin in the modulating effects of oleic
acid on plasminogen activation and plasmin activity described
above. When ﬁbrinogen clotting and plasminogen activation
were initiated simultaneously (Fig. 6), during the ascending
phase of the turbidity curves plasminogen activation occurred
in a ﬂuid ﬁbrinogen environment, where plasmin is susceptible
to the action of oleic acid. Thus, at increasing oleic acid
concentrations, more ﬁbrinogen was spared from plasmin
digestion, resulting in higher values of absorbance (oleic acid
on its own does not affect the clot turbidity in the absence of
plasmin formation; data not shown). During the descending
phase of the curves, when most of the ﬁbrinogen had already
been converted to ﬁbrin, the ﬁbrinolytic rate was hardly
affected by oleic acid (lysis time after maximal A340 in Fig. 6,
insets). The effect of oleic acid depended on the type of
activator; although less efﬁcient in the ﬂuid phase [26], reteplase
showed ﬁbrinolytic efﬁciency similar to that of t-PA in the
ﬁbrin-dependent stage of the assay (lysis time after maximal
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Fig. 1. Presence of free fatty acids in thrombi. Cryosections of thrombi were prepared and exposed to 100 lLo f2lmol L
)1 acrylodated intestinal fatty
acid-binding protein (ADIFAB) for 10 min. The ﬂuorescence at 460 nm (excitation 390 nm) was measured in 400 points of the section plane area with
dimensions x and y, and presented in relative ﬂuorescence units (RFU). (A) and (B) are representative scans of thrombi with high and low fatty acid
content, respectively. (C) shows the ﬂuorescence of 100 lLof2lmol L
)1ADIFAB containing 20 lmol L
)1sodium oleate, and(D) shows the ﬂuorescence
of 100 lLo f2lmol L
)1 ADIFAB in the absence of fatty acid.
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[9,10], oleic acid stimulated plasminogen activation by urok-
inase in this assay (data not shown). If 3 lmol L
)1 plasmino-
gen and 30 nmol L
)1 t-PA or reteplase were added together
with oleic acid (in the range 0.01–0.4 mmol L
)1) to the surface
of plasminogen-free ﬁbrin clots, a concentration-dependent
prolongation of the lysis time was detected (from 74.0 ±
4.9 min in the absence of oleic acid to 87.6 ± 2.6 min at the
highest oleic acid concentration with t-PA, and from 81.5 ±
5.0 min to 92.5 ± 3.0 min for reteplase).
Despite the decrease in the amidolytic and ﬁbrinolytic
activity of plasmin caused by oleic acid (Figs 4 and 5), the
susceptibility of the protease to its major plasma inhibitor, a2PI
was not modiﬁed signiﬁcantly in the ﬂuid phase (Fig. 7, inset).
As a result, oleic acid and a2PI (at the concentration detected in
human thrombi [27]) yielded additive inhibition of plasmin in
ﬁbrin clots (Fig. 7).
Discussion
Considering the known phospholipid content and PLA2release
from platelets and inﬂammatory cells in thrombi [3,5–7], the
thrombus localization of free fatty acids is not a surprising
ﬁnding, but their direct demonstration in human thrombi
(Fig. 1) is important evidence for the in vivo relevance of their
effects described by others [8–10] or reported now with respect
to thrombolysis. In addition, because of known inhibition of
other proteases by oleic acid (leukocyte elastase, gelatinases A
and B released by inﬂammatory cells) [28,29], the identiﬁcation
of free fatty acids in the structure of thrombi at varying (up to
millimolar) concentrations supports their in vivo role in the
modulation of inﬂammation-related proteolysis in this com-
partment. Because of the abundance of oleoyl side chains in
platelet phospholipids [4] and the reported data for the role of
unsaturated long-chain (more than 16 carbon atoms) fatty
acids in the modulation of plasmin and other proteases
[9,10,28], oleic acid was chosen as a model molecule.
Theoverallconceptthatemergesfromourresultsisthatoleic
acidisafactorthatcontributestothelocalizedactionofplasmin
in ﬁbrin clots; it favors plasmin generation on its surface, and at
the same time prevents the dissemination of protease activity in
thecirculationbecauseofitsinhibitoryeffectsinsolution.Using
an assay that selectively monitors plasminogen activation at the
interface of the ﬂuid phase (containing activator) and ﬁbrin
(containing plasminogen) [19], signiﬁcant acceleration of plas-
min generation by t-PA can be demonstrated in the presence of
oleic acid (Fig. 2A). A tenfold increase in the activation rate by
t-PA can be achieved within the range of oleic acid concentra-
tions relevant for thrombi (Table 1). This accelerating effect
does not require the ﬁbronectin ﬁnger-like, the epidermal
growth factor and kringle-1 domains of t-PA. Reteplase, a
recombinant variant of t-PA containing the kringle-2 and
proteasedomains,isstimulatedmorestronglybyoleicacidona
ﬁbrin surface (Fig. 2B, Table 1). The facts that kringle-2 is
involvedprimarilyininteractionswithlysineresidues[30],which
Fig. 2. Eﬀect of oleic acid on plasminogen activation in the presence of
ﬁbrin. Clear ﬁbrin clots containing plasminogen were prepared as des-
cribed in Methods, and 0.7 nmol L
)1 tissue-type plasminogen activator
(t-PA) (A) or reteplase (B) was added together with the plasmin substrate
Spectrozyme PL and varying concentrations of oleic acid, indicated by the
numbers (in mmol L
)1) next to the lines. The continuously monitored A405
is presented as mean and SD (dotted lines) of ﬁve measurements. Insets:
secondary plots of A405 vs. time squared; the slopes are linearly propor-
tional to the rate of plasmin generation.
Table 1 Relative eﬃciency of plasminogen activation in the presence of
oleic acid on ﬁbrin surface
Oleic acid
(mmol L
)1)
t-PA
[mean (SD)]
Reteplase
[mean (SD)]
0 1.00 (0.22) 1.00 (0.17)
0.025 1.29 (0.21) 1.78 (0.25)
0.05 1.81 (0.29) 4.18 (0.54)
0.7 7.37 (1.24) 14.54 (2.09)
1.4 10.19 (1.93) 35.78 (4.66)
The slopes of the linear plots in Fig. 2 (insets) reﬂect the rate of
plasmin generation in accordance with the equation given in Methods.
The ratios of these slopes in the presence of oleic acid and in its absence
are calculated for the respective activator, and their values are pre-
sented as mean and SD (in parentheses) of ﬁve measurements deter-
mined with a bootstrap procedure for a ratio of two measured
variables. The ratio of the baseline rates (in the absence of oleic acid) of
plasmin formation by equimolar concentrations of the two activators
(reteplase/tPA) is 0.54 (0.11).
t-PA, tissue-type plasminogen activator.
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theeffectofoleicacidisseenonlyinthepresenceofﬁbrinsuggest
that the acceleration of plasmin generation is based on
optimized formation of the ternary plasminogen–ﬁbrin–activa-
tor complex. The inhibition of plasminogen activation in the
ﬂuid phase (Fig. 3A) is reversed on the ﬁbrin surface (Fig. 2).
Such an effect can be expected if the modulator (oleic acid)
causes the template (ﬁbrin) to have higher afﬁnity for the
activator, so that more t-PA or reteplase is mobilized in
the reactive interfacial layer, and in addition the bound form of
the activator is less susceptible to the inhibitory effect of oleic
acid.Thisinterpretationisinlinewiththelackofanaccelerating
effect of oleic acid on plasminogen activation by urokinase,
which does not require a template. Thus, the presence of oleic
acid in thrombi may contribute to the therapeutic advantage of
ﬁbrin-speciﬁc plasminogen activators. On the other hand,
because the oleic acid effects vary between ﬁbrin-dependent
activators,itsroleasaﬁbrinolyticmodulatorinvivomayexplain
the lack of strict correlation between ﬁbrin binding and
Fig. 3. Eﬀect of oleic acid on plasminogen activation in solution. (A) The
activation mixture contained 1 lmol L
)1 plasminogen and 7 nmol L
)1
tissue-type plasminogen activator (t-PA). Samples taken at the indicated
time were treated with 100 mmol L
)1 Tris–HCl (pH 7.0) buﬀer containing
100 mmol L
)1 NaCl, 2% sodium dodecylsulfate, and 1% b-mercapto-
ethanol, and following electrophoresis on 10–15% polyacrylamide gel, the
protein bands were visualized with silver staining. Pg, plasminogen; Pn HC
and Pn LC, plasmin heavy and light chains, respectively. (B) The activa-
tion mixture contained 3 lmol L
)1 plasminogen, 100 lgm L
)1 cyanogen
bromide human ﬁbrinogen fragment, and 70 nmol L
)1 t-PA. Samples
were takenatthe times indicatedby symbols, andthe amidolytic activity of
the generated plasmin was measured on 0.1 mmol L
)1 Spectrozyme-PL.
The concentration of oleic acid in the activation stage of the assay is
indicated by the numbers next to the lines in mmol L
)1. The mean values
of two independent measurements are presented.
Fig. 4. Inhibition of the amidolytic activity of plasmin by oleic acid.
Plasmin at 25 nmol L
)1 was incubated with oleic acid for 15 min at 37  C
in 10 mmol L
)1 HEPES buﬀer (pH 7.4) containing 150 mmol L
)1 NaCl.
Then, 180 lLo ft h i sm i x t u r ew a sa d d e dt o2 0lLo f1m m o lL
)1 Spec-
trozyme PL, and the A405 was measured continuously for 1 min. The ratio
of DA min
)1 in the presence and absence of fatty acid is presented as
relative plasmin activity (mean and SD of ﬁve measurements). Inset: time
dependence of the inhibition of plasmin by oleic acid. The same meas-
urement was performed with plasmin incubated with 100 lmol L
)1 oleic
acid for various time intervals. At the times indicated by arrows, fatty acid-
free bovine serum albumin was added to the plasmin solutions (both the
oleic acid-free reference and the oleic acid-treated one) at 140 lmol L
)1
ﬁnal concentration (solid line), or the reaction mixture was diluted 5-fold
with buﬀer (dashed line), and plasmin activity was monitored further.
Fig. 5. Inhibition of the ﬁbrinolytic activity of plasmin by oleic acid. Fi-
brin clots were prepared from 6 lmol L
)1 ﬁbrinogen as described in
Methods, omitting the plasminogen. After 30 min, 60 lLo f1 0lmol L
)1
plasmin was added to the surface of the clot, followed by 60 lLo fm i n e r a l
oil. The plasmin solution contained no additive (solid line), 0.35 mmol L
)1
oleic acid (dashed line), or 1.4 mmol L
)1 oleic acid (dashed-and-dotted
line). Means and SDs (dotted lines) of ﬁve measurements are presented.
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of other known factors, such as different pharmacokinetics of
the activators in vivo.
In contrast to the situation with urokinase [10], t-PA-
catalyzed plasminogen activation is completely blocked by
oleic acid in ﬁbrin-free solution (Fig. 3A), which is related to
the effect of oleic acid on t-PA (its amidolytic activity on small
synthetic substrates is also inhibited; data not shown). CNBr
digestion of ﬁbrinogen exposes the binding sites for t-PA and
plasminogen that are necessary for its template function in
plasminogen activation (reviewed in [31]), and consequently
FgDP can at least partially relieve this inhibitory effect
(Fig. 3B). However, the already formed plasmin is also
inhibited by oleic acid in its amidolytic action in the ﬂuid
phase (Fig. 4) and to a lesser extent in its ﬁbrinolytic action
(Fig. 5). In the absence of an extensive ﬁbrin matrix, FgDP
cannot protect the already formed plasmin against the
inhibitory effect of oleic acid, and consequently plasmin is
not detected in the late stages of the activation assay with this
soluble template. A similar phenomenon is observed in the later
stages of the clot-dependent plasminogen activation assay
(Fig. 2), when the generated plasmin completely digests the
interfacial ﬁbrin layer to soluble products. The loss of enzyme
activity cannot be attributed to denaturation as a result of the
detergent effects of oleic acid, because the reactivity of plasmin
with macromolecular inhibitors is retained. In the presence of
oleic acid, the sensitivity of plasmin to its natural inhibitor a2PI
is preserved not only in free solution (Fig. 7, inset), but even on
the ﬁbrin surface (Fig. 7), which on its own is known to protect
the protease against a2PI [21,32]. Plasmin inhibition is revers-
ible (Fig. 4, inset), but the exact type of inhibition requires
further investigation. Probably, plasmin inhibition is based on
conformational changes in the protease domain induced by the
known binding of oleic acid to kringle-5 [9], whereas the
kringle-1-dependent interaction with a2PI [33] is not affected.
The effects of oleic acid on plasminogen activation and
plasmin activity contribute to a better understanding of the
in vivo data for ﬁbrinolytic potency and ﬁbrin speciﬁcity of
reteplase, and emphasize the need to perform enzymological
evaluationofthrombolyticsinanenvironmentthatcontainsnot
only ﬁbrin but also other modulators identiﬁed in thrombi.
Thus, reteplase is reported to have 2-fold to 4-fold lower
activator efﬁciency than the wild-type t-PA and to bind weakly
Fig. 6. Eﬀects of oleic acid on plasminogen activation and ﬁbrin(ogen)
degradation. One hundred microliters of 6 lmol L
)1 ﬁbrinogen contain-
ing 10 nmol L
)1 plasminogen and various concentrations of oleic acid (0,
continuous line; 100 lmol L
)1, dotted line; 200 lmol L
)1, dashed line;
400 lmol L
)1, dashed-and-dotted line) was added to 5 lLo f
0.2 lmol L
)1 thrombin and 5 lL of 100 nmol L
)1 tissue-type plasmino-
gen activator (A) or reteplase (B) in microplate wells, and after layering
60 lL of mineral oil on the surface, the absorbance at 340 nm was
recorded continuously at 37  C .M e a nv a l u e so ff o u rm e a s u r e m e n t sa r e
presented. Symbols indicate lysis time (t1/2). Insets: t1/2 values from the
start of the reactions (ﬁlled symbols) and after maximal A340 (open sym-
bols) from the same experiments, mean ± SD.
Fig. 7. Eﬀect of oleic acid on the plasmin inactivation by a2-plasmin
inhibitor (a2PI). Fibrin clots containing plasminogen were prepared as
described in Methods, and dissolution was initiated with 10 nmol L
)1
tissue-type plasminogen activator (t-PA) and monitored by measuring
absorbance at 340 nm. Some clots (dashed, dashed-and-dotted lines)
contained 0.25 lmol L
)1 a2PI, whereas some t-PA solutions contained
0.3 mmol L
)1 oleic acid (dotted, dashed-and-dotted lines). Symbols indi-
cate lysis time (mean ± SD of ﬁve measurements). Inset: eﬀect of oleic
acid on plasmin–a2PI complex formation. Plasmin (P, 0.25 lmol L
)1)a n d
a2PI (0.1 lmol L
)1) were incubated for the indicated times at 20  Ci nt h e
absence and presence of oleic acid. Samples of the reaction mixture were
taken at the indicated times (0 indicates sampling before mixing plasmin
and a2PI) and treated with 100 mmol L
)1 Tris–HCl (pH 7.0) buﬀer con-
taining 100 mmol L
)1 NaCl and 2% sodium dodecylsulfate. Following
electrophoresis on 12.5% polyacrylamide gel, the protein bands were
visualized with silver staining.
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but as a thrombolytic agent, it produces identical or even
improved clinical outcome [13]. Our data demonstrate a 2-fold
lower apparent reaction rate constant for plasminogen activa-
tionbyreteplaseascomparedtot-PAinplasminogenactivation
on a ﬁbrin surface (Fig. 2, insets), but this difference is reversed
in favor of reteplase in the presence of 1.4 mmol L
)1 oleic acid
(Table 1). When the action of the activators is evaluated in a
model system (Fig. 6), which monitors the consequences of
plasminogen activation with respect to both ﬁbrinogen and
ﬁbrin, oleic acid causes reteplase to have higher ﬁbrin speciﬁcity
andﬁbrinogen-sparingpropertiesascomparedtot-PA,because
its common inhibitory effect on plasmin is combined with more
pronounced ﬁbrin-dependent stimulation of plasminogen acti-
vation by reteplase. This conclusion is based on the changes in
lysis time at increasing concentrations of oleic acid (Fig. 6,
insets); because reteplase is less efﬁcient in solution [26], the
smalleramountsofplasmingeneratedbyitareeasilyblockedby
oleic acid (compare the ascending phase of the turbidity curves
in Fig. 6A,B), whereas there is hardly any difference in the
ﬁbrinolytic rate with the two activators when plasminogen is
activated predominantly on partially degraded ﬁbrin, to which
both activators can bind through their kringle-2 domains
(descending phase of the curves in Fig. 6). The experimental
setting of Fig. 6 also models the action of plasminogen
activators homogeneously entrapped in newly formed hemo-
static plugs in the course of thrombolytic therapy. Because the
premature dissolution of ﬁbrin clots is probably responsible for
the bleeding side-effects of thrombolytics, the similarity of t-PA
and reteplase in this assay may explain the identical rate of
hemorrhagic complications with these two activators [13].
In conclusion, our report provides evidence for the presence
of free fatty acids in thrombi, which optimize the ﬁbrin matrix
as a template for plasminogen activation by t-PA and thus
accelerate ﬁbrinolysis with activators that approach the clot
from the ﬂuid phase. Fibrin also partially protects plasmin and
t-PA against inhibition by oleic acid. In addition, a variant of
t-PA (reteplase), which is a less efﬁcient plasminogen activator
in a pure ﬁbrin environment, has an advantage over the wild-
type molecule in the presence of fatty acids. Analogous
evaluation (using assay formats that approach the complex
composition of thrombi) may explain why there is no obvious
correlation between ﬁbrin binding and the in vivo ﬁbrinolytic
efﬁciency of recombinant plasminogen activators. Finally, the
variability in the free fatty acid content of thrombi may
contribute to the variable therapeutic outcome of thrombolysis
in different patients.
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